AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said ...

AstraZeneca's hopes for baxdrostat are high, as in early 2023 it acquired the drug by purchasing its developer -- biotech ...

Shares in AstraZeneca rose past their September 2024 peak on Tuesday, hitting a fresh record high and cementing the company's ...

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

London's export-focused FTSE 100 rose to a new intraday record peak on Tuesday, buoyed by a weakening pound after economic ...

AstraZeneca is the stock to beat in the United Kingdom. The global pharmaceutical company saw its stock rise to its all-time ...

Blood-thinning drugs that doctors often prescribe interchangeably after procedures to reopen narrowed heart arteries don’t ...

Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan ...

AstraZeneca has won a shareholder vote approving plans for the FTSE 100’s largest company to elevate its New York listing, in ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.